文献速递神经肿瘤

原发性分子亚型分布差异导致成人型弥漫性胶质瘤的种族和民族差异

Differences in Primary Molecular Subtype Distribution Contribute to Racial and Ethnic Disparities in Adult-Type Diffuse Gliomas.
PubMed 文献 · Neuro Oncol · 2026-07-14

基于CBTRUS 2018-2022年68,172例胶质瘤病例和NCDB 2018-2021年生存数据,分析分子分型胶质瘤发病率和生存的种族/民族差异。非西班牙裔白人所有胶质瘤发病率显著更高,非西班牙裔黑人IDH突变型星形细胞瘤和少突胶质细胞瘤发病率最低。IDH野生型胶质母细胞瘤在各组中四年总生存率最低。

要点

  • 非西班牙裔白人所有胶质瘤发病率显著高于其他种族/民族组。
  • 非西班牙裔黑人IDH突变型星形细胞瘤和少突胶质细胞瘤发病率最低。
  • IDH野生型胶质母细胞瘤在所有种族/民族组中四年总生存率最低。

核心结论

  • 胶质瘤发病率和生存存在显著的种族/民族差异,且差异随胶质瘤生物标志物而变化。

主要发现

  • CBTRUS识别68,172例胶质瘤病例,IDH野生型胶质母细胞瘤最常见(n=51,548)。
  • 非西班牙裔白人所有胶质瘤发病率显著高于其他组(p>0.001)。
  • 非西班牙裔黑人IDH突变型星形细胞瘤和少突胶质细胞瘤发病率最低,与非西班牙裔其他个体共同为IDH突变型胶质母细胞瘤和IDH野生型星形细胞瘤发病率最低组,非西班牙裔其他个体IDH野生型胶质母细胞瘤发病率最低(p<0.001)。
  • 男性、年龄较大者和非西班牙裔黑人患IDH野生型(相对于IDH突变型)星形细胞瘤或胶质母细胞瘤的比值比显著更低(p<0.001)。
  • 非西班牙裔其他个体大多数胶质瘤亚型的调整后总生存增加(p<0.001);IDH野生型胶质母细胞瘤四年总生存在各组中最低(p<0.001)。

关键数值与推荐

  • 非西班牙裔白人所有胶质瘤发病率显著高于其他组(p>0.001)。
  • 非西班牙裔黑人IDH突变型星形细胞瘤和少突胶质细胞瘤发病率最低(p<0.001)。
  • 男性、年龄较大者和非西班牙裔黑人IDH野生型星形细胞瘤或胶质母细胞瘤比值比显著更低(p<0.001)。
  • 非西班牙裔其他个体大多数胶质瘤亚型调整后总生存增加(p<0.001)。
  • IDH野生型胶质母细胞瘤四年总生存在所有种族/民族组中最低(p<0.001)。

临床怎么用

  • 临床评估胶质瘤风险和预后时应考虑种族/民族与分子亚型的交互作用。
  • IDH野生型胶质母细胞瘤在各组中预后最差,需关注高危人群的早期识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular profiling has become an integral part of glioma classification. The extent to which incidence of molecularly-defined adult-type gliomas vary by demographics is unknown. We describe national-level incidence and overall survival patterns of selected glioma subtypes by race/ethnicity. METHODS: We generated standardized average annual age-adjusted incidence rates of molecularly-defined glioma subtypes by race/ethnicity from the Central Brain Tumor Registry of the United States (CBTRUS) using newly-diagnosed cases from January 1, 2018 to December 31, 2022. Survival data from the National Cancer Database (NCDB) were used from newly-diagnosed cases from January 1, 2018 to December 31, 2021 (with follow up through December 31, 2022) to evaluate four-year overall survival, median survival, and multivariable Cox Proportional hazards ratios. RESULTS: CBTRUS identified 68,172 glioma cases, IDH-wildtype glioblastoma was most common (n = 51,548). Non-Hispanic White individuals had significantly higher incidence of all gliomas compared to other groups (p > 0.001). Non-Hispanic Black individuals had the lowest incidence for IDH-mutant astrocytoma and oligodendroglioma, and shared lowest incidence of IDH-mutant glioblastoma and IDH-wildtype astrocytoma with non-Hispanic other individuals, who had the lowest incidence of IDH-wildtype glioblastoma (p < 0.001). The odds of having an IDH-wildtype (versus IDH-mutant) astrocytoma or glioblastoma were significantly lower for males, those of older age, and non-Hispanic Black individuals (p < 0.001). Non-Hispanic other individuals also had increased adjusted overall survival for most glioma subtypes compared to other racial/ethnic groups (p < 0.001). Four-year overall survival was lowest in all racial/ethnic groups for IDH-wildtype glioblastoma (p < 0.001). CONCLUSIONS: Our findings reveal significant disparities in incidence and survival by race/ethnicity with notable variations present based on glioma biomarkers. This study examined how often different genetically-defined brain tumors (gliomas) occur and how patients fare for different racial and ethnic groups in the U.S. Using national data, researchers found that non-Hispanic White individuals had the highest overall rates, while non-Hispanic Black individuals had lower rates for several tumor types. Survival also varied by group and tumor subtype. The most aggressive form of glioma had the worst survival outcomes for all groups. These findings highlight how race/ethnicity and tumor genetics play important roles in understanding who is diagnosed with gliomas and how well patients survive.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Gomez D, Shah I, Cote DJ, et al. Differences in Primary Molecular Subtype Distribution Contribute to Racial and Ethnic Disparities in Adult-Type Diffuse Gliomas. Neuro Oncol. 2026. PMID: 42446117. doi:10.1093/neuonc/noag157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。